These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

798 related items for PubMed ID: 19493258

  • 1. Results of retroperitoneal lymph node dissection after chemotherapy in patients with pure seminoma in the orchidectomy specimen but elevated serum alpha-fetoprotein.
    Peterson M, Beck S, Bihrle R, Einhorn L, Foster R.
    BJU Int; 2009 Jul; 104(2):176-8. PubMed ID: 19493258
    [Abstract] [Full Text] [Related]

  • 2. Long-term outcome for men with teratoma found at postchemotherapy retroperitoneal lymph node dissection.
    Svatek RS, Spiess PE, Sundi D, Tu SM, Tannir NM, Brown GA, Kamat AM, Wood CG, Pisters LL.
    Cancer; 2009 Mar 15; 115(6):1310-7. PubMed ID: 19156903
    [Abstract] [Full Text] [Related]

  • 3. Teratoma in primary testis tumor reduces complete response rates in the retroperitoneum after primary chemotherapy. The case for primary retroperitoneal lymph node dissection of stage IIb germ cell tumors with teratomatous elements.
    Rabbani F, Gleave ME, Coppin CM, Murray N, Sullivan LD.
    Cancer; 1996 Aug 01; 78(3):480-6. PubMed ID: 8697394
    [Abstract] [Full Text] [Related]

  • 4. Postchemotherapy retroperitoneal lymph node dissection is effective therapy in selected patients with elevated tumor markers after primary chemotherapy alone.
    Coogan CL, Foster RS, Rowland RG, Bihrle R, Smith ER, Einhorn LH, Roth BJ, Donohue JP.
    Urology; 1997 Dec 01; 50(6):957-62. PubMed ID: 9426730
    [Abstract] [Full Text] [Related]

  • 5. Primary vs. post-chemotherapy retroperitoneal lymph node dissection (RPLND) in patients with presence of teratoma at orchiectomy.
    Williams SB, Kacker R, Steele GS, Richie JP.
    Urol Oncol; 2012 Dec 01; 30(1):60-3. PubMed ID: 20189842
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Clinical parameters that predict histology of postchemotherapy retroperitoneal lymph node mass in testicular cancer.
    Onozawa M, Kawai K, Yamamoto T, Hinotsu S, Tsukamoto S, Hattori K, Miyanaga N, Shimazui T, Akaza H.
    Int J Urol; 2004 Jul 01; 11(7):535-41. PubMed ID: 15242364
    [Abstract] [Full Text] [Related]

  • 8. Incidence of metastatic nonseminomatous germ cell tumor outside the boundaries of a modified postchemotherapy retroperitoneal lymph node dissection.
    Carver BS, Shayegan B, Eggener S, Stasi J, Motzer RJ, Bosl GJ, Sheinfeld J.
    J Clin Oncol; 2007 Oct 01; 25(28):4365-9. PubMed ID: 17906201
    [Abstract] [Full Text] [Related]

  • 9. Retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer: impact of patient selection factors on outcome.
    Stephenson AJ, Bosl GJ, Motzer RJ, Kattan MW, Stasi J, Bajorin DF, Sheinfeld J.
    J Clin Oncol; 2005 Apr 20; 23(12):2781-8. PubMed ID: 15837993
    [Abstract] [Full Text] [Related]

  • 10. Postchemotherapy retroperitoneal lymph node dissection in advanced germ cell tumours of the testis.
    Heidenreich A, Thüer D, Polyakov S.
    Eur Urol; 2008 Feb 20; 53(2):260-72. PubMed ID: 18045770
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Pathologic findings and clinical outcome of patients undergoing retroperitoneal lymph node dissection after multiple chemotherapy regimens for metastatic testicular germ cell tumors.
    Eggener SE, Carver BS, Loeb S, Kondagunta GV, Bosl GJ, Sheinfeld J.
    Cancer; 2007 Feb 01; 109(3):528-35. PubMed ID: 17177200
    [Abstract] [Full Text] [Related]

  • 13. Outcome analysis for patients with elevated serum tumor markers at postchemotherapy retroperitoneal lymph node dissection.
    Beck SD, Foster RS, Bihrle R, Einhorn LH, Donohue JP.
    J Clin Oncol; 2005 Sep 01; 23(25):6149-56. PubMed ID: 16135481
    [Abstract] [Full Text] [Related]

  • 14. Retroperitoneal lymph node dissection after chemotherapy for germ cell tumours: is a full bilateral template always necessary?
    Steiner H, Peschel R, Bartsch G.
    BJU Int; 2008 Aug 01; 102(3):310-4. PubMed ID: 18325053
    [Abstract] [Full Text] [Related]

  • 15. Is post-chemotherapy resection of seminomatous elements associated with higher acute morbidity?
    Mosharafa AA, Foster RS, Leibovich BC, Bihrle R, Johnson C, Donohue JP.
    J Urol; 2003 Jun 01; 169(6):2126-8. PubMed ID: 12771733
    [Abstract] [Full Text] [Related]

  • 16. Clinical outcome following post-chemotherapy retroperitoneal lymph node dissection in men with intermediate- and poor-risk nonseminomatous germ cell tumour.
    Shayegan B, Carver BS, Stasi J, Motzer RJ, Bosl GJ, Sheinfeld J.
    BJU Int; 2007 May 01; 99(5):993-7. PubMed ID: 17437432
    [Abstract] [Full Text] [Related]

  • 17. Tumor marker levels in post-chemotherapy cystic masses: clinical implications for patients with germ cell tumors.
    Beck SD, Patel MI, Sheinfeld J.
    J Urol; 2004 Jan 01; 171(1):168-71. PubMed ID: 14665869
    [Abstract] [Full Text] [Related]

  • 18. The indication for postchemotherapy lymph node dissection in clinical stage IS nonseminomatous germ cell tumor.
    Dash A, Carver BS, Stasi J, Bajorin DF, Motzer RJ, Bosl GJ, Sheinfeld J.
    Cancer; 2008 Feb 15; 112(4):800-5. PubMed ID: 18172902
    [Abstract] [Full Text] [Related]

  • 19. Significance of primary tumor size and preorchiectomy serum tumor marker level in predicting pathologic stage at retroperitoneal lymph node dissection in clinical Stage A nonseminomatous germ cell tumors.
    Beck SD, Foster RS, Bihrle R, Donohue JP.
    Urology; 2007 Mar 15; 69(3):557-9. PubMed ID: 17382165
    [Abstract] [Full Text] [Related]

  • 20. [Two cases of testicular tumors with high alpha-fetoprotein levels: a case report].
    Funahashi M, Tuchiya F, Makiyama K, Sugiura S, Miyoshi Y, Kishida T, Ogawa T, Uemura H, Yao M, Kubota Y.
    Hinyokika Kiyo; 2005 Feb 15; 51(2):133-7. PubMed ID: 15773370
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 40.